Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies

3

4 Danyang Li, PhD 1,*, Oliver Pain, PhD 2, Chiara Fabbri, PhD 1,3, Win Lee Edwin Wong 1,4, Chris

- 5 Wai Hang Lo 1, Stephan Ripke, PhD 5,6, Annamaria Cattaneo, PhD 7,8, Daniel Souery, PhD 9, Mojca
- 6 Z. Dernovsek, MF 10, Neven Henigsberg, PhD 11, Joanna Hauser, PhD 12, Glyn Lewis, PhD 13, Ole
- 7 Mors, PhD 14, Nader Perroud, MD 15, Marcella Rietschel, MD 16, Rudolf Uher, MD 17, Wolfgang
- 8 Maier, MD 18, Katherine J. Aitchison, PhD 19, Bernhard T. Baune, MD 20,21,22, Joanna M. Biernacka,
- 9 PhD 23,24, Guido Bondolfi, MD 15, Katharina Domschke, MD 25, Masaki Kato, PhD 26, Yu-Li Liu,
- 10 PhD 27, Alessandro Serretti, PhD 3, Shih-Jen Tsai, MD 28,29, Richard Weinshilboum, MD 30, the
- 11 GSRD Consortium, the Major Depressive Disorder Working Group of the Psychiatric Genomics
- 12 Consortium, Andrew M. McIntosh, MD 31, Cathryn M. Lewis, PhD 1,32, *
- 13
- 14 1 = Social, Genetic and Developmental Psychiatry Centre, King's College London, London, GB
- 15 2 = Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, Institute of
 16 Psychiatry, Psychology and Neuroscience, King's College London, London, GB
- 17 3 = Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, IT
- 4 = Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore,
 Singapore, SG
- 20 5 = Department of Psychiatry and Psychotherapy, Universitätsmedizin Berlin Campus Charité Mitte, Berlin, DE
- 21 6 = Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, US
- 22 7 = Biological Psychiatry Laboratory, IRCCS Fatebenefratelli, Brescia, IT
- 23 8 = Department of Pharmacological and Biomedical Sciences, University of Milan, Milan, IT
- 9 = Laboratoire de Psychologie Medicale, Universitè Libre de Bruxelles and Psy Pluriel, Centre Européen de
 Psychologie Medicale, Brussels, BE
- 26 10 = University Psychiatric Clinic, University of Ljubliana, Ljubljana, SI
- 27 11 = Department of Psychiatry, Croatian Institute for Brain Research, University of Zagreb Medical School,
 28 Zagreb, HR
- 29 12 = Psychiatric Genetic Unit,, Poznan University of Medical Sciences, Poznan, PL
- **30** 13 = Division of Psychiatry, University College London, London, GB
- **31** 14 = Psychosis Research Unit, Aarhus University Hospital Psychiatry, Aarhus, DK
- **32** 15 = Department of Psychiatry, Geneva University Hospitals, Geneva, CH
- 33 16 = Department of Genetic Epidemiology in Psychiatry, Medical Faculty Mannheim, University of Heidelberg,
- 34 Central Institute of Mental Health, Mannheim, DE
- 35 17 = Department of Psychiatry, Dalhousie University, Halifax, NS, CA
- 36 18 = Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, DE
- 37 19 = Departments of Psychiatry and Medical Genetics and Neuroscience and Mental Health Institute, University
 38 of Alberta, Edmonton, AB, CA
- **39** 20 = Department of Psychiatry, University of Münster, Münster, DE
- 40 21 = Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, AU
- 41 22 = Department of Psychiatry, Melbourne Medical School, University of Melbourne, Melbourne, AU
- 42 23 = Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
- 43 24 = Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA
- 44 25 = Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Freiburg, DE
- 45 26 = Department of Neuropsychiatry, Kansai Medical University, Osaka, JP
- 46 27 = Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, TW
- 47 28 = Department of Psychiatry, Taipei Veterans General Hospital, Taipei, TW
- 48 29 = Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, TW
- 49 30 = Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN,
 50 USA
- 51 31 = Division of Psychiatry, University of Edinburgh, Edinburgh, GB
- 52 32 = Department of Medical & Molecular Genetics, King's College London, London, GB
- 53 * = Corresponding author54

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

55 Abstract

Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant 56 metabolism and polymorphisms of these genes have been determined to predict metabolite levels. 57 Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant 58 59 response. In this study, individual data from 13 clinical studies of European and East Asian ancestry 60 populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to four 61 62 metabolic phenotypes (poor, intermediate, normal, and ultrarapid) of CYP2C19 and CYP2D6. The 63 association of CYP2C19 and CYP2D6 metabolic phenotypes with treatment response was examined 64 using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance 65 (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033) but did not survive after multiple testing correction. No 66 metabolic phenotype was associated with percentage improvement from baseline. After stratifying by 67 antidepressants primarily metabolized by CYP2C19 and CYP2D6, no association was found between 68 metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in 69 70 frequency, but not effect, between European and East Asian studies. In conclusion, metabolic 71 phenotypes imputed from genetic variants were not associated with antidepressant response. CYP2C19 72 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. Information including side effects, antidepressant dosage, as well as population from different 73 74 ancestries could be involved to fully capture the influence of metabolic phenotypes and improve the 75 power of effect assessment.

76

77 Introduction

Antidepressants are the first-line treatment for moderate or severe depression, however efficacy varies, 78 79 and side effects are common¹. Approximately 35% of patients reach remission after treatment with a single antidepressant and a significant proportion of individuals develop treatment-resistant depression 80 defined as no remission attained after treatment with two or more antidepressants ²⁻⁴. Even within the 81 same antidepressant class, treatment responses vary substantially. For example, selective serotonin 82 83 reuptake inhibitors (SSRIs), the most widely prescribed antidepressants, could lead to remission in 30-84 45% of patients ⁵. Differences in response rate may be due to many factors including drug-drug interactions ⁶, depression subtypes ^{7,8}, comorbidity ⁹, smoking ¹⁰, and genetic variation, particularly in 85 drug metabolism genes. 86

87

88 Pharmacogenetics utilizes genetic variation that plays a role in medication action and metabolism to 89 facilitate individualized prescription, thus improving the treatment efficacy, and reducing undesirable effects¹¹. In antidepressants, current evidence and prescribing guidelines support two cytochrome P450 90 (CYP) genes (CYP2C19 and CYP2D6) for pharmacogenetic testing ^{11–14}. Both CYP2C19 and CYP2D6 91 are highly polymorphic, with genetic haplotypes defined by the star allele nomenclature ¹⁵. These star 92 93 alleles can be classified into different metabolic phenotypes: poor metabolizers (PMs), intermediate 94 metabolizers (IMs), normal metabolizers (NMs), and ultrarapid metabolizers (UMs) according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines ^{13,14}. Compared to NMs, 95 96 PMs and IMs have an increased risk of adverse effects because of a lower metabolism rate and elevated 97 drug serum concentrations, which may also increase treatment efficacy. UMs, on the other hand, 98 facilitate the metabolic process to reduce drug exposure and may lead to treatment failure through a lack of efficacy. 99

100

Clinical studies have shown that genetic variation in these metabolizing enzymes is clearly associated 101 with metabolite levels, but the link between genetic variation and treatment response or side effects is 102 more complicated. For example, in the GENDEP study, CYP2C19 and CYP2D6 genotypes were 103 associated with serum concentration of escitalopram and nortriptyline, but did not predict treatment 104 response ¹⁶. A meta-analysis of 94 studies assessed the relationship between psychiatric drug exposure 105 (dose-normalized plasma level) and metabolising status of CYP2C19 and CYP2D6, observing exposure 106 differences in escitalopram and sertraline ¹⁷. However, treatment effectiveness of these antidepressants 107 was not associated with CYP2C19 genotypes in a large retrospective study based on participant self-108 report¹⁸. 109

110

Guidelines have been developed for antidepressant use based on CYP2D6 and CYP2C19 metabolizing status. For instance, CPIC guidelines for CYP2D6, suggest a 50% dose reduction of fluvoxamine, paroxetine and most tricyclic antidepressants for PMs, and alternative antidepressants that are not predominantly metabolized by CYP2D6 are advised for UMs ^{13,14}. However, evidence is still accruing to confirm the role of pharmacogenetic testing to guide antidepressant prescribing ¹¹. Therefore, further studies are required to provide additional evidence to reach an agreement on appropriate antidepressant prescribing based on pharmacogenetic testing of CYP2C19 and CYP2D6 in clinical use.

118

In this study, we combined clinical and genetic data from 13 clinical studies, with 5843 participants, to examine the association of CYP2C19 and CYP2D6 metabolic phenotypes with clinically evaluated treatment response across multiple antidepressants. We investigated whether genotype-determined PMs, IMs, and UMs of CYP2C19 and CYP2D6 showed differential antidepressant efficacy, compared to NMs. This unique resource provides additional evidence of the relationship between CYP gene

metabolic phenotypes and treatment response, and may further determine whether metabolizer statuscould add useful information for individualized prescribing of antidepressants.

126

127 Methods

128 Samples

The clinical studies analysed have been described in detail previously ³. In brief, 10 studies with 129 European ancestry and 3 studies from East Asia were included. All participants had a diagnosis of major 130 depressive disorder (MDD) and received at least one antidepressant, with treatment response collected 131 at baseline, and for 4-12 weeks post-baseline. We assessed two antidepressant response outcomes of 132 remission and percentage improvement. Remission was a binary outcome defined as a reduction of the 133 depression symptoms to a prespecified criteria of the rating scale. Percentage improvement was a 134 continuous measure calculated from the proportional decrease (or increase) of depression symptom 135 score from baseline. The percentage improvement was standardized (mean 0, standard deviation 1) 136 137 within study to allow comparability of different scales across the studies (e.g. HAMD (Hamilton 138 Depression Rating Scale), MADRS (Montgomery Åsberg Depression Rating Scale), QIDSC (Quick 139 Inventory of Depressive Symptomatology)). Demographic and clinical variables of age, sex, MDD baseline severity and antidepressant prescription information were available in each study 140 (Supplementary Table 1). 141

Detailed procedures of genotyping have been reported elsewhere ^{19–27}. Quality control and imputation were processed using the standard 'RICOPILI' pipeline from the Psychiatric Genomics Consortium (PGC) with 1000 Genomes Project multi-ancestry reference panel ²⁸. Each step was performed separately in European and East Asian ancestry studies following standard PGC protocols. Study details can be found in Supplementary Table 1 and the previous study ³.

147

148 Star alleles and metabolic phenotypes

Using best guess imputed genotype calls, phasing was conducted separately on the genetic regions of 149 CYP2C19 and CYP2D6 obtained from PharmGKB (https://www.pharmgkb.org/). The haplotype was 150 determined in each sample using SHAPEIT4 software and the 1000 Genomes Project multi-ancestry 151 reference panel²⁹. To fully utilize phased SNPs and translate them to star alleles, we first extracted all 152 SNPs used to define CYP2C19 and CYP2D6 star alleles from the CPIC definition tables 153 (https://cpicpgx.org/; downloaded June 2022). These SNPs were then matched to the phased data, and 154 matching SNPs were assigned to star alleles following the CPIC guidelines. If a star allele was defined 155 by more than one SNP, it was counted only when all the defined SNPs were observed. Each star allele 156 was annotated as having no, decreased, normal, or increased function with corresponding activity value 157 based on CPIC definition tables and the previous literature (Supplementary Table 2)^{14,30}. The reference 158 159 allele (*1) was assigned to haplotypes that had no annotated functional star alleles or had uncertain or unknown functional alleles of CYP2D6. Because structural variants cannot be determined from 160 genotype data, CYP2D6 ultrarapid metabolisers were not included. Next, we calculated the activity 161 score for each individual by adding the activity values of the two star alleles. Metabolic phenotypes 162 (PM, IM, NM, UM) were determined following consensus recommendations from the CPIC and the 163 Dutch Pharmacogenetics Working Group (DPWG)^{14,31,32}. In our study, ultrarapid metabolisers were 164 defined as individuals carrying at least one increased functional allele. To validate the defined metabolic 165 phenotypes, we compared phenotype concordance with that previously derived in the GENDEP using 166 Roche AmpliChip CYP450 microarray and TaqMan SNP genotyping ¹⁶. After harmonizing the 167 metabolizer status, the concordance rate (percentage of individuals assigned the same metabolic 168 phenotypes) was 96.4% for CYP2C19 and 79.9% for CYP2D6 (Supplementary Table 3). 169

170

171 Statistical analyses

172 - Associations

We used the NMs in CYP2C19 and CYP2D6 as the reference group to examine the effect of other 173 metabolizer groups on antidepressant response. For remission, logistic regression was used to evaluate 174 the association with CYP2C19 and CYP2D6 metabolic phenotypes in each study, using age, sex, and 175 MDD baseline severity as covariates. For percentage improvement, linear regression with CYP2C19 176 and CYP2D6 metabolic phenotypes, adjusting for age and sex, was used to test for association with 177 178 metabolic phenotypes. The correlation between MDD baseline score and percentage improvement was 179 very low (Pearson correlation = 0.042), so we did not add MDD baseline severity as a covariate. We next stratified into 'antidepressant groups', with drugs that were primarily metabolised by either 180 CYP2C19 or CYP2D6, based on the clinical annotation of Level 1A in PharmGKB ^{12,33}(Supplementary 181 Table 4). Stratifying participants by CYP2C19- and CYP2D6-metabolised antidepressants, we repeated 182 the analyses of remission and percentage improvement in 10 studies with CYP2C19-metabolised 183 antidepressants (3390 participants) and 6 studies with CYP2D6-metabolised antidepressants (1223 184 185 participants) (Supplementary Figure 1).

186

187 - Meta-analyses

In each study, odds ratios (ORs) of remission, and Standard Mean Differences (SMDs, Cohen's D) of 188 percentage improvement, with standard errors of both effect sizes, for each metabolizer group were 189 extracted. We applied random effect meta-analysis since the true effects were assumed to be 190 heterogeneous due to the difference in factors such as study populations, antidepressants prescribed, 191 192 and outcome measurements. The effect sizes in each study were pooled, and inverse-variance weighted. The between-study heterogeneity was quantified by I^2 statistic and heterogeneity variance τ^2 using the 193 194 Paule-Mandel method for ORs and restricted maximum-likelihood estimator for SMDs. The 195 significance was tested by Cochran's Q at p < 0.05. Additionally, subgroup meta-analyses were applied to test the hypothesis that effects differed between European and East Asian ancestry. We assumed both 196 ancestries shared a common between-study heterogeneity (τ^2) due to a small number of studies from 197 198 East Asia. Cochran's Q was used to determine whether the differences between subgroups could be 199 explained by true effect differences or by sampling errors alone. We performed meta-analyses in all samples for CYP2C19 and CYP2D6 metabolic phenotypes and then stratified the analyses by 200 201 antidepressant groups for the corresponding metabolizer effects. We used p value < 0.05 as nominal significance, and corrected for multiple testing for the 5 independent tests of metabolic phenotypes 202 203 compared with NMs (3 phenotypes in CYP2C19 and 2 phenotypes in CYP2D6), giving a Bonferroni 204 corrected p value of 0.01 (0.05/5). No correction across outcomes (remission and percentage 205 improvement) was applied, due to their high correlations. All meta-analyses were performed by 'meta' package in R 4.2.1. 206

The power of the meta-analysis was calculated by 'dmetar' package in R 4.2.1. Using the sample size of PMs (N = 179) and NMs (N = 2289) in CYP2C19, the meta-analysis had over 80% power to detect SMD of 0.074 and OR 1.15 with no effect heterogeneity, or SMD 0.085 and OR 1.17 with low heterogeneity, at a significance level p = 0.01.

211

212 Sensitivity tests

213 Three sensitivity analyses were performed. Firstly, each participant's activity score was calculated as a 214 continuous measure to assess metabolic activity and compared to the metaboliser groups. We tested

215 CYP2C19 and CYP2D6 metabolic effects represented by activity scores using the same analyses

- 216 described above. For the percentage improvement outcome, correlations were assessed between activity
- 217 scores and residuals of percentage improvement after regressing out age and sex, and restricted

218 maximum-likelihood estimator was used to estimate between-study heterogeneity of correlations in the

219 meta-analyses. Secondly, the impact of baseline depression severity on percentage improvement was

assessed by including it as a covariate in the linear regression analyses. Finally, to test how small studies

- 221 might be impacting results, we reran the meta-analysis of CYP2C19 PM on the remission outcome
- including only studies with at least 10 PMs present.

223224 Results

225 Characteristics of star alleles and metabolic phenotypes

Seven star alleles in CYP2C19 and 16 alleles in CYP2D6 were identified from the imputed genotype 226 227 data and were classified as having no, decreased, normal and increased function (Supplementary Table 2). In general, alleles had similar frequencies in studies of the same ancestry group (Supplementary 228 Figure 2). The reference alleles (*1) were the most common, with mean frequency 62.8% in CYP2C19, 229 230 and 39.2% in CYP2D6 in European ancestry studies, and frequencies of 62.1% and 34.2% in East Asian 231 studies. Other high frequency alleles in European-ancestry studies were *17 (22.0%) in CYP2C19 and *4 (19.8%) in CYP2D6, while CYP2C19 *2 (30.5%) and CYP2D6 *10 (48.6%) had high frequencies 232 in East Asian. A total of 5843 individuals with remission or percentage improvement outcome in 13 233 234 studies were analysed. Four metabolizer groups (PM, IM, NM, UM) for CYP2C19 and three metabolizer groups (PM, IM, and NM) for CYP2D6 were translated from star alleles. In both genes, 235 the most common metabolizer group was NM, and the rarest was PM (Table 1). Compared with the 236 East Asian, the European population had a lower proportion of PM and IM in CYP2C19, and higher 237 proportion of PM in CYP2D6 (Figure 1, differences between ancestries, Wilcoxon test: CYP2C19 PM 238 p = 0.007, CYP2C19 IM p = 0.007, CYP2C19 UM p = 0.007, CYP2D6 PM p = 0.014). For the 12 239 240 antidepressants metabolized primarily by either CYP2C19 or CYP2D6, the same distribution of metabolic phenotypes was found in both antidepressant groups (Supplementary Table 5). 241

242

243 Meta-analyses of CYP2C19 and CYP2D6 metabolic phenotypes in all samples

The association of metabolizer status with antidepressant response was first assessed in all samples. 244 The remission rate and mean percentage improvement in each metabolizer group are presented in Table 245 246 1. Overall, PMs in CYP2C19 showed a higher remission rate with nominal significance (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033, Figure 2a) but did not meet correction for multiple testing. The 247 percentage improvement analysis showed a non-significant higher efficacy in PMs (SMD = 0.13, 95%248 CI [-0.03, 0.29], p = 0.101). Other metabolic phenotypes in CYP2C19 and CYP2D6 had no difference 249 from NMs in both outcomes (Figure 2a). Subgroup meta-analyses found no heterogeneity in the effect 250 of CYP2C19 PMs in all cohorts or between ancestry groups. In other metabolic phenotypes of both 251 genes, no significant heterogeneity was detected (Supplementary Figure 3, 4). 252

253

254 Meta-analyses of CYP2C19 and CYP2D6 metabolic phenotypes stratified by antidepressant 255 groups

Next, to determine if the metabolic activity was associated with response in antidepressants that were 256 primarily metabolized by CYP2C19 or CYP2D6¹², meta-analyses were stratified with 7 CYP2C19-257 metabolised antidepressants and 9 for CYP2D6 (Supplementary Table 4). CYP2C19 PMs showed a 258 similar trend to the results in all samples, with a higher remission rate and percentage improvement 259 compared to NMs (remission: OR = 1.47, 95% CI [0.90, 2.39], p = 0.121; percentage improvement: 260 SMD = 0.12, 95% CI [-0.10, 0.34], p = 0.282, Figure 2b, c) but the association was not significant. 261 262 Other metabolizer groups were not associated with response. Detailed results for each study can be found in Supplementary Figures 5 and 6. As a comparison, metabolic effect was tested in the 263 264 antidepressant groups that were not primarily metabolised by CYP2C19 or CYP2D6. Detailed results are shown in Supplementary Figure 7. 265

266

267 Sensitivity test

Finally, three sensitivity tests were performed. First, the meta-analyses were repeated using the activity 268 score as a quantitative measurement of metabolic activity to compare the results with the primary 269 analyses. The activity scores differed between European and East Asian studies, with Europeans having 270 higher scores for both CYP2C19 and CYP2D6 (Wilcoxon test: CYP2C19 p = 0.007; CYP2D6 p =271 0.028, Supplementary Figure 8). However, activity score was not associated with the outcomes of 272 remission or percentage improvement (Supplementary Table 6). In the second sensitivity test, baseline 273 274 severity of depression was added as an additional covariate in the analyses of percentage improvement. 275 As in the primary analyses, PMs in CYP2C19 had higher, but non-significant SMD of percentage improvement (SMD = 0.13, 95% CI [-0.03, 0.29], p = 0.103). No clear pattern was found in tests of 276 other metabolizers (Supplementary Table 7). Lastly, we meta-analysed the CYP2C19 PMs for 277 remission by including only studies with more than 10 CYP2C19 PMs. A higher rate of remission was 278 observed in CYP2C19 PMs from 8 studies confirming the association found in the main analyses (OR 279 = 1.56, 95% CI [1.09; 2.24], p = 0.016). 280

282 Discussion

281

283 In this study, we leveraged 13 clinically defined studies (10 of European-ancestry and 3 from East Asia) to meta-analyse the association of CYP2C19 and CYP2D6 metabolic phenotypes with antidepressant 284 285 response, using remission and percentage improvement as outcome measures. Using the available imputed genotype data, we identified 7 star alleles of CYP2C19 and 16 star alleles of CYP2D6. We 286 found CYP2C19 PMs had a higher remission rate compared to CYP2C19 NMs in all samples (OR =287 1.46; 95% CI [1.03, 2.06]), which reached nominal significance but was not significant at the multiple 288 289 testing threshold. CYP2C19 PMs also had a higher remission rate in antidepressants primarily metabolised by CYP2C19 (OR = 1.47, 95% CI [0.90, 2.39]) but differences were not significant. No 290 difference in percentage improvement was seen between PMs and NMs. Other metabolizer groups in 291 292 CYP2C19 and CYP2D6 showed no association with either remission or percentage improvement. Although there were differences in the frequency of star alleles and in the proportions of metabolic 293 phenotypes between European and East Asian studies, the impact of metabolic phenotypes was similar. 294 295

Our analysis pipeline for calling star alleles from genotype data detected 7 star alleles of CYP2C19 296 including all tier 1 alleles (*2, *3 and *17) and two tier 2 alleles (*8, *35) demonstrating a good 297 coverage of imputed genotype for *CYP2C19* region ³⁴. Nevertheless, only a moderate relationship was 298 detected with CYP2C19 PMs with the remission outcome. Other metabolizer status was not associated 299 300 with the outcome. When testing the PMs restricted to antidepressants largely metabolised by CYP2C19, a similar effect size was detected but showed no significance, suggesting a loss of power. Other meta-301 analyses, retrospective studies, and clinical cohorts have replicated a higher antidepressant efficacy of 302 CYP2C19 PMs^{18,35–37}. However, a null effect or an opposite association of CYP2C19 slow metabolizers 303 for lower antidepressant efficacy was observed in smaller samples ^{16,38,39}. This discrepancy may be due 304 to different criteria for study participants, MDD severity, dropout rates, medication prescribed, and lack 305 of information on other associated factors such as antidepressant dosage. Given the heterogeneity of 306 307 patients and potential confounding variables, our results need further replication to understand the role 308 of CYP2C19 metabolizers under different circumstances. In addition to treatment efficacy, PMs of 309 CYP2C19 were also associated with worse antidepressant tolerability, although these features were not assessed in our study ^{18,36}. CPIC and the Dutch Pharmacogenetics Working Group (DPWG) have 310 recommended reducing the starting dose of escitalopram, citalopram, and sertraline for CYP2C19 PMs 311 because of the increased probability of adverse effects ^{14,31}. Appropriate support could be provided to 312 313 patients at the beginning of the treatment to reduce the dropout rate and maximize the drug effect.

314

CYP2D6 has higher variability and more star alleles than CYP2C19, including common, rare, and 315 316 structural variants which make genotype analysis more challenging. In our study, 16 star alleles of CYP2D6 were classified as having no, decreased, or normal function. No structural variants (such as *5 317 allele) could be detected using imputed genotypes, so increased function alleles were not called. 318 Previous studies have shown that 7% of CYP2D6 variants were structural variants, so the star allele 319 calls, diplotype assignment and metabolic phenotype could be affected by missing structural variants 320 ^{40,41}. Unlike a previous meta-analysis of clinical trials showing strong associations of CYP2D6-guided 321 antidepressant treatment with improved patient outcomes ⁴², we found no association between CYP2D6 322 metabolizer status and treatment outcome in all samples or in the CYP2D6-antidepressant group. Thus, 323 our results should be explained with caution and need to be compared with further studies using 324 325 available genotype data.

326

327 Activity score was also applied for the assignment of metabolic phenotype. Using clinical guidelines, each allele from CYP2C19 and CYP2D6 is assigned an activity value and the value is summed across 328 the two alleles carried to give an activity score representing the individual's metabolic activity ^{30,32,37}. 329 330 We found no effect of activity score on the outcomes of remission and percentage improvement. These 331 antidepressant results contrast to antipsychotic response, where higher CYP2C19 activity score was associated with lower symptom severity ³⁰. The previous association of CYP2C19 PMs with remission 332 outcome was not detected in the activity score analysis. This is likely because PMs have a low frequency 333 and represent only the lower tail of the activity score distribution, so the effect is diluted when 334 combining phenotype groups. 335

336

337 Our analyses included both European and East Asian ancestry populations. The frequencies of star 338 alleles were clustered by ancestry. For example, European population had lower frequencies of *2, *3 339 in CYP2C19 and *10 in CYP2D6, but higher frequencies of CYP2C19 *17 and CYP2D6 *4, than the East Asian population, leading to fewer PMs and IMs for CYP2C19 but higher proportions of CYP2C19 340 UMs and CYP2D6 PMs. These ancestry differences align with the CPIC guideline and other reports 341 342 ^{14,43}. When connecting the cytochrome enzyme status with antidepressant response, few studies have been performed in the East Asian population. A clinical trial of 100 depression patients from Taipei 343 found CYP2D6 intermediate metabolizers had higher frequency of remitters and CYP2C19 poor 344 metabolizers had higher serum levels of antidepressants⁴⁴. In some antipsychotics metabolized by 345 specific cytochrome enzymes, the plasma concentrations of drugs are higher in East Asian populations 346 than in European populations ⁴⁵. In contrast, modelling has suggested that the metabolic contributions 347 of CYP2C19 on escitalopram would be similar across European and Asian populations ⁴⁶. As there is 348 little evidence of differentiation by ancestry, current clinical guidelines provide the same antidepressant 349 dosing recommendations across populations¹⁴. Our subgroup meta-analyses between the European and 350 East Asian studies also found no heterogeneity of metabolic effect for both genes but the low sample 351 size in East Asian studies (9% of all samples) was poorly powered compared to the European studies. 352 353

Some study limitations should be considered. Primarily, larger sample sizes are needed specifically in 354 355 different ancestries and drug groups. Even though most studies were of European ancestry, too few CYP2C19 PMs (2.1% in European, 3.1% in all participants) were present to show a statistically 356 significant effect after correcting for multiple testing. Similarly, CYP2C19 UMs (1.1%) and CYP2D6 357 PMs (< 0.1%) were rare in the East Asian population. Citalopram and escitalopram were the most 358 prescribed drugs, accounting for 54% of all samples and 93% of the CYP2C19 antidepressant group, 359 360 so the metabolic effect on treatment response was mainly determined by these two drugs. In addition, no data from clinical evaluations or the environment (e.g. dosage, concomitant drugs, smoking, diet) 361

362 were analysed, and these factors could influence symptom improvement and cytochrome metabolic activity. No significant differences between IMs/UMs and NMs could be detected, and higher power is 363 364 probably needed to effectively test between metabolizer groups. Side effects were also not available in 365 our data, which are associated with metabolic phenotypes. We analysed only the final depression score, at the end of the study treatment, to determine remission and calculate the percentage improvement. 366 Other studies have suggested using longitudinal measures throughout treatment period as repeated 367 measures in a mixed linear model to improve the statistical power ³⁸. Finally, structural variants in 368 CYP2D6 cannot be detected using genotype data, so no CYP2D6 UMs were identified. Deeper 369 imputation panels that detect structure variants, or further genetic studies using sequencing or a targeted 370 array would be necessary for a full assessment of CYP2D6 metaboliser status ⁴⁷. 371

372

In conclusion, using imputed genotype data, our meta-analysis showed no significant association
between cytochrome metabolic phenotypes with antidepressant response. Moderate evidence of an
association with CYP2C19 poor metabolizers was indicated, which had higher rates of antidepressant

- remission. Metabolic phenotypes differed in frequency between European and East Asian populations,
- 377 but did not differ in their effect on treatment outcomes. More samples with patient information and
- ancestry diversity could be collected to improve the power and accuracy for a fuller assessment of the
- effect of metabolic phenotypes on antidepressant response.
- 380

381 Acknowledgements

The collection of the sample from the Group for the Study of Resistant Depression (GSRD) Consortium
was supported by an unrestricted grant from Lundbeck for the GSRD. Lundbeck had no further role in
the study design and the collection, analysis, and interpretation of data.

The GENDEP (Genome Based Therapeutic Drugs for Depression) study was funded by a European Commission Framework 6 grant (EC Contract Ref. No. LSHB-CT-2003-503428). H. Lundbeck provided nortriptyline and escitalopram for the GENDEP study. GlaxoSmithKline and the UK National Institute for Health Research of the Department of Health contributed to the funding of the sample collection at the Institute of Psychiatry, London. GENDEP Illumina array genotyping was funded in part by a joint grant from the UK Medical Research Council and GlaxoSmithKline (Grant No. G0701420).

The GENPOD (GENetic and clinical Predictors Of treatment response in Depression) trial was funded 392 by the UK Medical Research Council and supported by the UK Mental Health Research Network. The 393 394 genotyping of GENPOD samples was supported by the Innovative Medicine Initiative Joint 395 Undertaking under Grant No. 115008, of which resources are composed of European Union and the 396 European Federation of Pharmaceutical Industries and Associations (EFPIA) in-kind contribution and 397 financial contribution from the European Union's Seventh Framework Programme (Grant No. 398 FP7/2007-2013). EFPIA members Pfizer, GlaxoSmithKline, and F. Hoffmann-La Roche have contributed work and samples to the project presented here. The PFZ (Pfizer), GSK (GlaxoSmithKline), 399 400 and GODS were supported by the Innovative Medicine Initiative Joint Undertaking (IMI-JU) under Grant No. 115008 of which resources are composed of European Union and EFPIA) in-kind 401 402 contribution and financial contribution from the European Union's Seventh Framework Programme 403 (FP7/2007-2013). EFPIA members Pfizer, GlaxoSmithKline, and F. Hoffmann La-Roche have 404 contributed work and samples to the project presented here.

405 **PGRN-AMPS** (Pharmacogenomics Network The Research Antidepressant Medication Pharmacogenomic Study) study data were obtained via the database of Genotypes and Phenotypes 406 (dbGAP) (Accession No. phs000670.v1.p1). Funding support for the PGRN-AMPS study was provided 407 by the National Institute of General Medical Sciences, National Institutes of Health, through the PGRN 408 grant to Principal Investigators R. Weinshilboum and L. Wang (Grant No. U19 GM61388). D. Mrazek 409 410 served as the Principal Investigator for the PGRN-AMPS study within the Mayo Clinic PGRN program. 411 Genome-wide genotyping was performed at the RIKEN Center for Genomic Medicine, with funding 412 provided by RIKEN. The datasets used for the analyses described in this manuscript were obtained from

413 the dbGaP at http://www.ncbi.nlm.nih.gov/gap/.

- 414 Major funding for the Psychiatric Genetics Consortium (PGC) is from the U.S. National Institutes of
 415 Health (Grant Nos. U01 MH109528 and U01 MH109532).
- 416 Statistical analyses for the PGC were carried out on the NL Genetic Cluster Computer 417 (http://www.geneticcluster.org) hosted by SURFsara.
- 418 For the purposes of open access, the author has applied a Creative Commons Attribution (CC BY)
- 419 licence to any Accepted Author Manuscript version arising from this submission.

420421 Conflict of Interest

- 422 CML has served on the scientific advisory board for Myriad Neuroscience, and is a consultant for UCB.
- KJA has received two research grants in the last 2 years from Janssen Inc., Canada (fellowship grants
 for trainees), and provided consultancy services in the last three years for Otsuka Canada
 Pharmaceutical Inc., Lundbeck Canada, and HLS Therapeutics.
- AS is or has been consultant/speaker for: Abbott, AbbVie, Angelini, AstraZeneca, Clinical Data,
 Boehringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, InnovaPharma, Italfarmaco, Janssen,
- 428 Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, and Servier.
- AMM has received research support from the Sackler Trust and speakers fees from Janssen andIllumina.
- 431 MK has received grant funding from the Japanese Ministry of Health, Labor and Welfare, the Japan
- 432 Society for the Promotion of Science, SENSHIN Medical Research Foundation, the Japan Research
- 433 Foundation for Clinical Pharmacology and the Japanese Society of Clinical Neuropsychopharmacology
- and speaker's honoraria from Sumitomo Pharma, Otsuka, Meiji-Seika Pharma, Eli Lilly, MSD K.K.,
- Pfizer, Janssen Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical,
 Lundbeck Viatris Inc, Eisai Co., Ltd. and Ono Pharmaceutical and participated in an advisory/review
- 437 board for Otsuka, Sumitomo Pharma, Shionogi and Boehringer Ingelheim.
- 438 DS has received grant/research support from GlaxoSmithKline and Lundbeck; and served as a 439 consultant or on advisory boards for AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, and
- 440 Lundbeck.
- 441 CF was a speaker for Janssen.
- 442 NP is or has been consultant/speaker for: Takeda, Janssen and Lundbeck
- 443 All other authors report no biomedical financial interests or potential conflicts of interest.

445 Funding

- 446 This study was supported by the NIMH (MH124873) and by the NIHR Maudsley Biomedical Research
- 447 Centre at South London and Maudsley NHS Foundation Trust and King's College London.
- 448 Chiara Fabbri and Alessandro Serretti were partly supported by #NEXTGENERATIONEU (NGEU),
- 449 funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan
- 450 (NRRP), project MNESYS (PE0000006) A Multiscale integrated approach to the study of the nervous
- 451 system in health and disease (DN. 1553 11.10.2022).
- 452

444

453 Data and code availability

- 454 Analysis code is available on the github: <u>https://github.com/DanyangLi107/PGC_CYP2gene</u>.
- 455

456 References

- 457 1. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline NG222. (2022).
- 459 2. Fabbri, C. *et al.* Genetic and clinical characteristics of treatment-resistant depression using primary
 460 care records in two UK cohorts. *Mol. Psychiatry* 26, 3363–3373 (2021).
- 461 3. Pain, O. *et al.* Identifying the Common Genetic Basis of Antidepressant Response. *Biol. Psychiatry*462 *Glob. Open Sci.* 2, 115–126 (2022).
- 463 4. Trivedi, M. H. et al. Evaluation of Outcomes With Citalopram for Depression Using
- 464 Measurement-Based Care in STAR*D: Implications for Clinical Practice. *Am. J. Psychiatry* 163,
 465 28–40 (2006).

- 466 5. Carvalho, A. F., Cavalcante, J. L., Castelo, M. S. & Lima, M. C. O. Augmentation strategies for treatment-resistant depression: a literature review: Augmentation strategies for TRD. *J. Clin.*468 *Pharm. Ther.* 32, 415–428 (2007).
- 469 6. Bleakley, S. Antidepressant drug interactions: evidence and clinical significance: Antidepressant drug interactions. *Prog. Neurol. Psychiatry* 20, 21–27 (2016).
- Fabbri, C., Pain, O., Hagenaars, S. P., Lewis, C. M. & Serretti, A. Transcriptome-wide association
 study of treatment-resistant depression and depression subtypes for drug repurposing. *Neuropsychopharmacology* 46, 1821–1829 (2021).
- 474 8. Fava, M. *et al.* Major depressive subtypes and treatment response. *Biol. Psychiatry* 42, 568–576
 475 (1997).
- 476
 9. Iosifescu, D. V., Bankier, B. & Fava, M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. *Curr. Psychiatry Rep.* 6, 193–201 (2004).
- 478 10. Oliveira, P., Ribeiro, J., Donato, H. & Madeira, N. Smoking and antidepressants
 479 pharmacokinetics: a systematic review. *Ann. Gen. Psychiatry* 16, 17 (2017).
- 480 11. Bousman, C. A. *et al.* Review and Consensus on Pharmacogenomic Testing in Psychiatry.
 481 *Pharmacopsychiatry* 54, 5–17 (2021).
- 482 12. Bousman, C. A., Zierhut, H. & Müller, D. J. Navigating the Labyrinth of Pharmacogenetic
 483 Testing: A Guide to Test Selection. *Clin. Pharmacol. Ther.* 106, 309–312 (2019).
- Hicks, J. K. *et al.* Clinical pharmacogenetics implementation consortium guideline (CPIC) for
 CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. *Clin. Pharmacol. Ther.* 102, 37–44 (2017).
- Hicks, J. K. *et al.* Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline
 for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. *Clin. Pharmacol. Ther.* 98, 127–134 (2015).
- 490 15. Kalman, L. V. *et al.* Pharmacogenetic allele nomenclature: International workgroup
 491 recommendations for test result reporting. *Clin. Pharmacol. Ther.* 99, 172–185 (2016).
- 492 16. Hodgson, K. *et al.* Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. *J. Psychopharmacol. (Oxf.)* 28, 133–141 (2014).
- 494 17. Milosavljević, F. *et al.* Association of CYP2C19 and CYP2D6 Poor and Intermediate
 495 Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and
 496 Meta-analysis. *JAMA Psychiatry* 78, 270–280 (2021).
- 497 18. Campos, A. I. *et al.* Impact of CYP2C19 metaboliser status on SSRI response: a retrospective
 498 study of 9500 participants of the Australian Genetics of Depression Study. *Pharmacogenomics J.*499 22, 130–135 (2022).
- Baffa, A. *et al.* Norepinephrine and Serotonin Transporter Genes: Impact on Treatment
 Response in Depression. *Neuropsychobiology* 62, 121–131 (2010).
- Baune, B. T. *et al.* Association of the COMT val158met Variant with Antidepressant
 Treatment Response in Major Depression. *Neuropsychopharmacology* 33, 924–932 (2008).
- 504 21. Biernacka, J. M. *et al.* The International SSRI Pharmacogenomics Consortium (ISPC): a
 505 genome-wide association study of antidepressant treatment response. *Transl. Psychiatry* 5, e553
 506 (2015).
- Domschke, K. *et al.* Monoamine oxidase A variant influences antidepressant treatment
 response in female patients with Major Depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 32, 224–228 (2008).
- 510 23. Fabbri, C. *et al.* Genome-wide association study of treatment-resistance in depression and 511 meta-analysis of three independent samples. *Br. J. Psychiatry* **214**, 36–41 (2019).
- 512 24. Garriock, H. A. *et al.* A Genome-Wide Association Study of Citalopram Response in Major
 513 Depressive Disorder. *Biol. Psychiatry* 67, 133–138 (2010).
- 514 25. Mrazek, D. A. *et al.* Treatment Outcomes of Depression: The Pharmacogenomic Research
 515 Network Antidepressant Medication Pharmacogenomic Study. *J. Clin. Psychopharmacol.* 34, 313–
 516 317 (2014).
- 517 26. Tansey, K. E. *et al.* Genetic Predictors of Response to Serotonergic and Noradrenergic
 518 Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level
 519 Data and a Meta-Analysis. *PLoS Med.* 9, (2012).

- 520 27. Uher, R. *et al.* Genome-wide pharmacogenetics of antidepressant response in the GENDEP
 521 project. *Am. J. Psychiatry* 167, 555–564 (2010).
- 522 28. Lam, M. *et al.* RICOPILI: Rapid Imputation for COnsortias PIpeLIne. *Bioinformatics* 36, 930–933 (2020).
- 524 29. Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T. Accurate,
 525 scalable and integrative haplotype estimation. *Nat. Commun.* 10, 5436 (2019).
- 30. Okhuijsen-Pfeifer, C. *et al.* Genome-wide association analyses of symptom severity among
 clozapine-treated patients with schizophrenia spectrum disorders. *Transl. Psychiatry* 12, 145
 (2022).
- 31. Brouwer, J. M. J. L. *et al.* Dutch Pharmacogenetics Working Group (DPWG) guideline for
 the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. *Eur. J. Hum. Genet.* (2021)
 doi:10.1038/s41431-021-01004-7.
- 532 32. Caudle, K. E. *et al.* Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus
 533 Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch
 534 Pharmacogenetics Working Group. *Clin. Transl. Sci.* 13, 116–124 (2020).
- 535 33. Whirl-Carrillo, M. *et al.* An Evidence-Based Framework for Evaluating Pharmacogenomics
 536 Knowledge for Personalized Medicine. *Clin. Pharmacol. Ther.* 110, 563–572 (2021).
- 537 34. Pratt, V. M. *et al.* Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A
 538 Report of the Association for Molecular Pathology. *J. Mol. Diagn.* 20, 269–276 (2018).
- 539 35. Calabrò, M. *et al.* Metabolizing status of CYP2C19 in response and side effects to
 540 medications for depression: Results from a naturalistic study. *Eur. Neuropsychopharmacol.* 56, 100–111 (2022).
- 542 36. Fabbri, C. *et al.* Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. *Eur.*544 *Neuropsychopharmacol.* 28, 945–954 (2018).
- 545 37. Mrazek, D. A. *et al.* CYP2C19 Variation and Citalopram Response. *Pharmacogenet*.
 546 *Genomics* 21, 1–9 (2011).
- 547 38. Islam, F. *et al.* Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and
 548 aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study. *Transl.*549 *Psychiatry* 12, 366 (2022).
- 550 39. Joković, D. *et al.* CYP2C19 slow metabolizer phenotype is associated with lower 551 antidepressant efficacy and tolerability. *Psychiatry Res.* **312**, 114535 (2022).
- 552 40. Del Tredici, A. L. *et al.* Frequency of CYP2D6 Alleles Including Structural Variants in the
 553 United States. *Front. Pharmacol.* 9, 305 (2018).
- 41. Pratt, V. M. *et al.* Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A
 Joint Consensus Recommendation of the Association for Molecular Pathology, College of
 American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists
 Association, and the European Society for Pharmacogenomics and Personalized Therapy. *J. Mol. Diagn.* 23, 1047–1064 (2021).
- 42. Arnone, D. *et al.* Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19
 genomic variants for guiding the treatment of depressive disorders: Systematic review and metaanalysis of randomised controlled trials. *Neurosci. Biobehav. Rev.* 144, 104965 (2023).
- 562 43. Zhou, Y., Ingelman-Sundberg, M. & Lauschke, V. M. Worldwide Distribution of Cytochrome
 563 P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. *Clin. Pharmacol. Ther.*564 102, 688–700 (2017).
- 565 44. Tsai, M.-H. *et al.* Genetic polymorphisms of cytochrome P450 enzymes influence metabolism
 566 of the antidepressant escitalopram and treatment response. *Pharmacogenomics* 11, 537–546
 567 (2010).
- Lin, S.-K. Racial/Ethnic Differences in the Pharmacokinetics of Antipsychotics: Focusing on
 East Asians. J. Pers. Med. 12, 1362 (2022).
- 570 46. Zhou, L. *et al.* Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese,
 571 Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based
 572 pharmacokinetic modelling. *Eur. J. Pharm. Sci.* 139, 105061 (2019).
- 47. McInnes, G. *et al.* Pharmacogenetics at Scale: An Analysis of the UK Biobank. *Clin. Pharmacol. Ther.* 109, 1528–1537 (2021).
- 575

Figure legends:

Figure 1. Proportion of metabolic phenotypes in each cohort Figure 2. Association of CYP2C19 and CYP2D6 metabolizer status with antidepressant outcomes

Table 1. Sample characteristics

	CYP2C19				CYP2D6		
	Poor (N=179)	Intermediate (N=1601)	Normal (N=2289)	Ultrarapid (N=1774)	Poor (N=249)	Intermediate (N=2087)	Normal (N=3507)
Remission	89 (49.7%)	607 (37.9%)	885 (38.7%)	662 (37.3%)	96 (38.6%)	796 (38.1%)	1351 (38.5%)
Percentage Improvement	0.12 (1.10)	0.00 (0.98)	-0.01 (1.01)	0.00 (0.99)	-0.02 (0.98)	0.01 (0.98)	0.00 (1.00)
Age	45.15 (14.53)	44.76 (14.64)	44.44 (14.19)	44.95 (14.17)	43.41 (14.62)	44.51 (14.29)	44.91 (14.31)
Sex (Female)	112 (62.6%)	987 (61.6%)	1438 (62.8%)	1112 (62.7%)	154 (61.8%)	1301 (62.3%)	2194 (62.6%)
Ancestry (European)	110 (61.5%)	1360 (84.9%)	2078 (90.8%)	1768 (99.7%)	249 (100%)	1902 (91.1%)	3165 (90.2%)
CYP2D6							
Poor	7 (3.9%)	55 (3.4%)	96 (4.2%)	91 (5.1%)	-	-	-
Intermediate	58 (32.4%)	598 (37.4%)	785 (34.3%)	646 (36.4%)	-	-	-
Normal	114 (63.7%)	948 (59.2%)	1408 (61.5%)	1037 (58.5%)	-	-	-

Mean with standard deviation for continuous variables and frequency with proportion for categorical variables were displayed





Figure 1. Proportion of metabolic phenotypes in each cohort

DAST: Depression and Sequence of Treatment, GENDEP: Genome Based Therapeutic Drugs for Depression, GENPOD: GENetic and clinical Predictors Of treatment response in Depression, GODS: Geneva Outpatient Depression Study, GSK: Glaxo Smith Kline, GSRD: Group for the Study of Resistant Depression, PFZ: Pfizer, PGRN: Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study, STARD, Sequenced Treatment Alternatives to Relieve Depression.

Figure 2. Association of CYP2C19 and CYP2D6 metabolizer status with antidepressant outcomes



PM: poor metabolizer, IM: intermediate metabolizer, UM: ultrarapid metabolizer, OR: odd ratio, SMD: standard mean difference, CI: confidence interval